These results provide evidence that inhibition of PDK1 may have greater anti-cancer therapeutic benefits in breast cancer patients with higher IGF-I/IGFR-I levels, and that a combination therapy featuring a PDK1 inhibitor and an IGFR-I inhibitor may have synergistic effects in this patient population. The gene discussed is PDK1; the disease is breast carcinoma.